Blockchain Registration Transaction Record

BioVersys Publishes BV100 Lung Penetration and Drug Interaction Data

BioVersys announces publication of BV100 Phase 1 data in two leading journals, showing high lung penetration and mild drug interactions, supporting Phase 3 development for CRAB pneumonia.

The publication of these Phase 1 data in leading antimicrobial journals underscores BV100's potential as a much-needed new treatment for carbapenem-resistant <em>Acinetobacter baumannii</em> pneumonia, a condition with limited treatment options and mortality rates up to 50%. The high lung penetration and manageable drug-interaction profile support further clinical development and could lead to a new therapeutic option for critically ill patients, addressing a significant unmet medical need in the fight against multidrug-resistant infections.